Operational Costs Compared: SG&A Analysis of Pfizer Inc. and Ultragenyx Pharmaceutical Inc.

Pfizer vs. Ultragenyx: A Decade of SG&A Strategies

__timestampPfizer Inc.Ultragenyx Pharmaceutical Inc.
Wednesday, January 1, 20141409700000010811000
Thursday, January 1, 20151480900000033001000
Friday, January 1, 20161483700000064936000
Sunday, January 1, 20171478400000099909000
Monday, January 1, 201814455000000127724000
Tuesday, January 1, 201914350000000161524000
Wednesday, January 1, 202011615000000182933000
Friday, January 1, 202112703000000219982000
Saturday, January 1, 202213677000000278139000
Sunday, January 1, 202314771000000309799000
Monday, January 1, 202414730000000
Loading chart...

Igniting the spark of knowledge

A Decade of SG&A: Pfizer vs. Ultragenyx

In the ever-evolving pharmaceutical landscape, operational efficiency is key. Over the past decade, Pfizer Inc. and Ultragenyx Pharmaceutical Inc. have showcased contrasting strategies in managing their Selling, General, and Administrative (SG&A) expenses. Pfizer, a titan in the industry, consistently maintained SG&A expenses around $14 billion annually, with a slight dip in 2020. This reflects a stable operational strategy, even amidst global challenges. In contrast, Ultragenyx, a burgeoning biotech firm, exhibited a dynamic growth trajectory. From a modest $10 million in 2014, their SG&A expenses surged to over $300 million by 2023, marking a staggering 2,800% increase. This rapid escalation underscores Ultragenyx's aggressive expansion and investment in innovation. As the pharmaceutical sector continues to evolve, these financial strategies offer a glimpse into the diverse paths companies take to achieve growth and sustainability.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025